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Abstract
Exposure to radiation during fetal development induces testicular germ cell tumors (TGCT) and reduces spermatogenesis in
mice. However, whether DNA damaging chemotherapeutic agents elicit these effects in mice remains unclear. Among such
agents, cyclophosphamide (CP) is currently used to treat breast cancer in pregnant women, and the effects of fetal exposure
to this drug manifested in the offspring must be better understood to offer such patients suitable counseling. The present
study was designed to determine whether fetal exposure to CP induces testicular cancer and/or gonadal toxicity in 129 and
in 129.MOLF congenic (L1) mice. Exposure to CP on embryonic days 10.5 and 11.5 dramatically increased TGCT incidence to
28% in offspring of 129 mice (control value, 2%) and to 80% in the male offspring of L1 (control value 33%). These increases
are similar to those observed in both lines of mice by radiation. In utero exposure to CP also significantly reduced testis
weights at 4 weeks of age to ,70% of control and induced atrophic seminiferous tubules in ,30% of the testes. When the
in utero CP-exposed 129 mice reached adulthood, there were significant reductions in testicular and epididymal sperm
counts to 62% and 70%, respectively, of controls. In female offspring, CP caused the loss of 77% of primordial follicles and
increased follicle growth activation. The results indicate that i) DNA damage is a common mechanism leading to induction
of testicular cancer, ii) increased induction of testis cancer by external agents is proportional to the spontaneous incidence
due to inherent genetic susceptibility, and iii) children exposed to radiation or DNA damaging chemotherapeutic agents in
utero may have increased risks of developing testis cancer and having reduced spermatogenic potential or diminished
reproductive lifespan.
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Introduction
In the past 50 years, the incidence of testicular germ cell tumors
(TGCTs) among Caucasian men age 15–40 years, the group in
which these malignancies occur most frequently, has increased 3-
fold [1]. Men’s sperm production has also declined constantly over
the last six decades [2]. Both of these adverse outcomes are
suggested to be the result of prenatal exposure to environmental
agents, mainly endocrine disruptors [3]. Nevertheless, there are no
unequivocal studies showing endocrine disruptors to be the
causative factors behind an increase in TGCT incidence [4,5].
Furthermore, there is a rise in early menopause (premature
ovarian failure) in women that seems to be largely attributable to
increased survival of cancer patients treated with radiotherapy and
chemotherapy as children or young women [6]; however, the
contribution of fetal exposures have not been examined.
The 129 mouse model [7], which has a 5% incidence of
testicular teratomas, is the only animal model of human TGCTs,
and although whether results using this model can be extrapolated
to tumors arising in young men is still a matter of some debate,
there are many similarities. These teratomas are histologically and
developmentally similar to human teratomas. In both humans and
mice, teratomas arise during early postnatal development due to a
failure of the pluripotent PGCs, arriving at the genital ridge, to
differentiate into gonocytes committed to spermatogenesis [7,8].
Further, both are predisposed by mutations in the Kitl or Dmrt1
genes [9–12], and both appear to involve epigenetic changes in
their etiology [13,14].
In a previous study, we found that the TGCT incidence of mice
exposed to low doses of ionizing radiation in utero was dramatically
increased above than that of control mice [5]. We also found that,
non–tumor-bearing testes were significantly smaller at 28 days of
age, compared with unirradiated counterparts, indicating reduced
spermatogenesis. Extrapolation of these findings to human
conditions led us to hypothesize that radiation exposure in utero
may increase males’ risks of TGCT and infertility. However, given
the relatively low radiation doses that women of childbearing age
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currently receive, it is unlikely that radiation in utero has been
responsible for the global elevation in the TGCT incidence and
decline in sperm counts. Rather, exposure to a chemical whose
primary biological mechanism of action is similar to that of
radiation could be responsible for these adverse outcomes.
Because radiation acts by DNA damage, we hypothesized that
DNA-damaging chemicals, particularly the highly carcinogenic
alkylating agents, may be candidates for the induction of TGCT.
We chose to examine the effects of cyclophosphamide (CP)
because it has been widely studied and is used to treat pregnant
women such as those with breast cancer as part of the FAC (5-
fluorouracil, Adriamycin, cyclophosphamide) combination che-
motherapy regimen [15]. CP could be carcinogenic to the embryo
as it has high transplacental transfer in non-human primates [16],
induces DNA strand breaks in mouse embryos [17], and causes
secondary malignancies in cancer patients [18]. In addition CP is a
major reproductive toxicant in male and female mice [19,20] and
prepubertal and adult humans exposed to CP can develop
permanent azoospermia and premature ovarian failure [21,22].
However, its effects on carcinogenesis and reproductive function
after fetal exposures have not been yet investigated.
We therefore hypothesized that in utero CP exposure may be
carcinogenic to the testis and induce reproductive toxicity in both
sexes. We used the 129 as well as the more sensitive 129.MOLF-
L1 testis cancer mouse model for testing induction of TGCT by
this chemical and also to test testicular toxicity. Only 129 mice
were used to test the ovarian toxicity. Exposures were done at
E10.5 and 11.5 which is known to be a sensitive stage for induction
of testicular cancers [5,7]. In addition there are only 1,000 to
3,000 germ cells at these ages and the stromal cells are just being
formed, making both the gonadal germ cells and stromal cells
targets for reproductive toxicity.
Materials and Methods
Mice and breeding
Inbred congenic 129.MOLF-L1 mice, referred to as L1, had
been derived by crossing 129S1/SvImJ and MOLF/Ei inbred
mice of the Mus musculus molossinus subspecies [23]. About 30% of
L1 males develop spontaneous testicular tumors. In addition,
129S1/SvImJ (Jackson Laboratories, Bar Harbor, ME) and 129/
S5 (previously obtained from Taconic and maintained in our
laboratory) mice, both of which have ,5% incidence of
spontaneously developed TGCTs were also used. No major
significant differences between the results with the two 129
sublines were observed, so that the data could be combined.
All experimental procedures were approved by the MD
Anderson Cancer Center Institutional Animal Care and Use
Committee with approved protocol numbers 110712632 and
110712633. The mice used in the study were housed in facilities at
MD Anderson that are registered by the U.S. Department of
Agriculture and accredited by the American Association for the
Accreditation of Laboratory Animal Care.
Treatments
Timed matings were performed with pairs of L1 or 129 mice.
Pregnant females were irradiated with two doses of 0.8 Gy of
6uCo-gamma radiation given on days 10.5 and 11.5 of their
pregnancy (E10.5 and E11.5) as described previously [5]. The
male offspring of 129 and L1 dams from the same breeding
colonies that did not receive any of these treatments or
manipulations were analyzed as controls.
Pregnant 129 or L1 mice were injected (ip) with CP, dissolved in
saline at doses of 7.5 mg/kg on days 10.5 and 11.5 of pregnancy.
The offspring from dams of the same breeding colony that
received saline on these days were used as controls.
Analysis
Male offspring exposed to cyclophosphamide or radiation in
utero and control male offspring were euthanized at 4 weeks of age,
because most testicular tumors are readily observable at this age
[23]. To determine the effects of in utero cyclophosphamide
exposure on spermatogenesis in adults, some offspring of 129Sv
mice were kept until 8 weeks of age and then euthanized. The
testes were weighed and then fixed in Bouin’s solution for
histologic examination and tumors were identified by the analysis
of hematoxylin and eosin-stained sections, as described previously
[5].
In sections from normal non-tumor-bearing testes of 4-week-old
mice, the numbers of moderately large atrophic tubules without
any germ cells (Sertoli-only tubules), observed mostly in the
interior region of a single mid-cross section of the testis, were
counted. The small atrophic tubules present in the peripheral
region near the rete testes were excluded from this analysis.
Occasional testes in the control or treatment groups that had
.20% atrophic tubules, possibly due to an inherent abnormality,
were excluded from this analysis or from testis weight averages.
Historical data from a previous study on the induction of
TGCT in in utero irradiated L1 mice [5] were also used for
comparison.
Sperm production was assessed in adult 129 mice that did not
bear tumors. One of the testes was homogenized after weighing
and sonicated. The sperm heads were counted in a hemocytom-
eter [24]. For epididymal sperm counts, both cauda epididymides
were minced separately in 1 ml PBS and incubated at 37uC for
30 min, and the suspension was passed through a 80-mm pore size
metal filter. Sperm were counted using a hemocytometer.
To analyze the effects of in utero CP exposure on ovarian
follicular development, female pups were euthanized at 7 days
after birth and the ovaries were fixed in Bouin’s fluid. The ovaries
were paraffin-embedded and serially sectioned at 5-mm thickness
and slides were stained with hematoxylin and eosin.
To determine changes in ovarian volume, every 10th slide was
used to generate an area measurement using the Image-Pro Plus
software. These area measurements were then used to calculate
the ovarian volume based on the thickness of the sections and the
total number of slides comprising the ovary.
To count different types of follicles, one section from every 10th
slide was imaged using a 406 objective and tiled [25]. Follicles
were classed as either primordial (having a single flattened layer of
granulosa cells); primary transitional (having some, but not all, of
the granulosa cells already cuboidal); primary (having a single
layer of cuboidal granulosa cells); or secondary (having more than
one layer of cuboidal granulosa cells). The total number of
follicles/ovary were calculated from the raw follicle counts per
section using the Abercrombie equation [26] to correct for follicle
size.
Statistical Analysis
Numerical data are presented as mean 6 standard errors of the
means. The significance of differences in continuous variables (e.g.
litter size, weights, sperm counts, tubular or follicular numbers)
between exposed and control mice were evaluated by a Student’s t-
test. The significance of the differences in categorical variables (e.g.
production of progeny, presence of tumors or atrophic tubules)
between exposed and control mice were determined using the
Fisher’s exact test. P values ,0.05 were considered statistically
Gonadal Dysgenesis by Fetal Exposure to Cyclophosphamide
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significant. A computer-assisted statistics program (IBM SPSS
version 19) was used.
The data for the offspring of the CP controls (in utero saline-
treated mice) and radiation-controls (offspring of untreated mice)
were not significantly different (with one exception indicated in
Table S1) and were pooled together.
Results
Pregnant 129 (129S1/SvImJ and 129S5) and L1 mice were
treated with two doses of CP, one at each of days 10.5 and 11.5 of
pregnancy. Initial studies tested doses of 25 and 10 mg/kg given
on both days, but, although all females survived, 0/15 and 0/7
plug-positive females, respectively, produced offspring. When the
CP dose was reduced to 7.5 mg/kg/day, 24% and 31% of the
successfully mated 129 and L1 mice, respectively, produced
progeny (Table 1). The percentage of progeny-producing CP-
treated 129 dams (24%) was significantly lower than that of the
control dams (50%) but was not significantly different from that of
the radiation-treated dams (33%). However, CP or radiation did
not affect litter sizes. In addition, mice exposed to radiation or CP
did not show any major teratogenic effects, except that most of the
mice exposed to CP in utero had kinks in their tails (Fig. S1).
Overall, there were small but significant reductions in the body
weights of the mice after fetal exposure to either CP and radiation.
Testes were harvested from the male offspring and the presence
and types of tumors was determined by histological examination
(Fig. 1 A & B). Exposure to CP during pregnancy significantly
(P,0.001) increased TGCT incidence in the male offspring of 129
mice from a control value of 2% to 28% and in L1 mice from 33%
to 80% (Table 2). In both mouse strains, the higher incidence of
tumors among mice exposed to CP in utero was similar to that of
mice exposed to radiation in utero. The numbers of mice with
unilateral or bilateral tumors followed a binomial distribution,
indicating that the occurrence of a tumor in each testis was an
independent event. Thus expressing the data on a per testis basis,
CP induced TGCTs in 18% of the testes in 129 mice and in 64%
of the testes in L1 mice. Most of these tumors were teratomas
(Fig. 1A); the rest contained only neuroepithelial tumor cells
(Fig. 1B). Compared with those of control mice, the TGCT-
bearing testes of L1 mice, but not 129 mice, exposed to CP or
radiation were significantly heavier. This suggests that both CP-
and radiation induced multiple tumor foci in some of the testes of
L1 mice. To determine whether minor differences in genetic
makeup affected tumor induction, we compared these results on
induced TGCT incidence of 129S1/SvImJ mice to those of 129S5
mice (Table S1). There was only a marginally significant difference
(P=0.04) with higher incidence of TGCTs in CP-treated 129S5
mice than in CP-treated 129S1/SvImJ mice.
Furthermore, at 28 days of age the weights of tumor-free testes
of 129 and L1 mice exposed to CP in utero were reduced to 74%
and 72%, respectively, of those of the control mice (Table 3);
similar to the decrease observed with 260.8 Gy radiation in utero.
This reduction in testis weight did not appear to be the result of
body weight loss, as the ratio of the testis weight to body weight of
the toxicant-exposed mice was also significantly lower than that of
the control mice. Atrophic Sertoli cell-only tubules were frequently
observed in the groups of treated mice (Fig. 1 C & D) but rarely
observed in the controls. For example, about 30% of the testes
from the CP- or radiation-treated 129 mice had atrophic tubules
with an average of 6 per testis section (Table 3). In contrast
atrophic tubules were observed in only 4% of the testes from
control mice, with an average of 1.6 atrophic tubules per section.
Even when in utero CP-exposed 129 mice reached adulthood, the
weights of the testes remained reduced to 78% of control values
(Table 4). Reductions in the counts of testicular and epididymal
sperm to 62% and 70%, respectively, of controls were observed in
these mice after in utero CP exposure, demonstrating that germ cell
loss was primarily responsible for the reduction in testis weights.
In female offspring, in utero exposure to CP significantly reduced
the volume of ovaries to a value of 5.560.66107 mm3, compared
to 13.061.46107 mm3 in controls (P=0.001; Fig. 1 E & F). In
these mice, the numbers of primordial follicles per ovary was only
23% of control mice (Table 5 and Fig. 1 G & H). Interestingly,
although mice exposed to CP in utero had lower numbers of
growing (transitional primary, primary, and secondary) follicles
than controls, the ratio of the total number of developing follicles
to the number of primordial follicles was increased from 0.23 in
controls to 0.62 in in utero CP-exposed offspring (P,0.05).
Table 1. Effect of cyclophosphamide (CP) or radiation on days 10.5 and 11.5 after mating on breeding efficiency of 129 and L1
mice.
Mouse strain Treatment
Vaginal plug positive
mice Produced progeny a Average litter size
Body weight of male offspring at 28
days (g) b
129 c Control 20 10 (50%) 4.960.5 14.860.3
129 c CP 130 31 (24%) d 4.560.4 13.360.4e
129 c Control ND ND 5.160.4 16.360.4
129 c Radiation 52 17 (33%) 5.460.7 14.460.3e
L1 Control 12 7 (58%) 5.160.6 16.860.5
L1 CP 39 12 (31%) 5.460.4 12.760.3e
L1 Control f ND ND 6.46 0.7 16.860.4
L1 Radiation f 28 15 (54%) 5.360.6 14.460.5e
Abbreviation: ND, no data.
aValues given as absolute number and percentage of total vaginal plug-positive females.
bThe number of male offspring per group ranged from 19 to 51.
cData from 129S5 and 129S1/SvImJ mice were pooled.
dSignificantly different between treated and control mice (P,0.05; Fisher’s exact test).
eSignificantly different between treated and control mice (P,0.05; t test).
fHistorical data from previous study [5] were used for comparison.
doi:10.1371/journal.pone.0093311.t001
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Discussion
In the present study we demonstrated for the first time that
chemical exposure during fetal development can induce TGCTs.
We also demonstrated that in utero exposure to radiation or CP
dramatically increases the incidence of testicular tumors in 129
mice, thereby extending our previous findings using L1 mice,
which are highly susceptible to testicular tumors [5], to a
commonly used strain of mice that is only moderately susceptible
to such tumors. The qualitative and quantitative similarities in the
induction of TGCTs between the mice exposed to radiation in utero
and those in mice exposed to CP in utero indicate that radiation and
Figure 1. Histology of testes and ovaries from 129 mice exposed to cyclophosphamide at 7.5 mg/kg/day on E10.5 and 11.5. (A-D)
Testes from 4-week-old mice. (A) TGCT characterized as a teratoma originating from multiple dermal layers; (B) TGCT containing only neuroepithelial
cells. Abbreviations: BM: bone marrow; CA: cartilage; EEP: endodermal epithelium; NE: neuroepithelial cells; MS: muscle; ST: seminiferous tubule. (C)
non-TGCT-bearing testis showing active and atrophic tubules. (D) High magnification of atrophic tubules containing only Sertoli cells. (E-H) Ovaries
from 7-day-old mice. (E, G) From a mouse treated on E10.5 and 11.5 with 7.5 mg CP/kg/day. (F, H) Control ovary of the same age. G and H are the
magnified views from portions of E and F respectively, showing primordial (PO), primary-transitional (PT) and primary (PR) follicles. The bar represents
100 mm in A, B, C, E & F; 30 mm in D; 10 mm in G and H.
doi:10.1371/journal.pone.0093311.g001
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CP have similar mechanisms of testicular tumorigenesis. We also
showed that these in utero-exposures resulted in marked reductions
in germ cell numbers in ovaries of female offspring and in the
testes of male offspring that did not develop tumors.
The time points for exposure to potential carcinogenic agents
for induction of TGCTs were initially chosen at E10.5 and E11.5
[5] since those are the earliest days just after the PGCs colonize the
fetal gonad and are undergoing extensive epigenetic changes [14].
Furthermore, the PGCs still express pluripotency markers and
have the ability to form teratomas in transplantation assays [7],
which are lost by day E13.5. The demonstration of susceptibility to
induction of TGCTs during this time window for two agents, CP
and radiation, and for two strains of mice, 129 and L1, supports
this choice. Although other ages have not yet been investigated, it
is most likely that the window of sensitivity to induction of TGCTs
by radiation and CP is limited to E10.5 to E12.5 in mice, which is
the period in mice during which the PGCs are in the testes and are
pluripotent, and not yet committed to germ cell lineages.
Previous studies have shown that single exposures of low-dose
(,1.5 Gy) radiation delivered between E14.5 and birth cause
long-term damage to spermatogenesis in both mice [27] and rats
[28]. The findings of the present study suggest that this window of
sensitivity to radiation is even longer, extending to as early as
E11.5 or E10.5. The effects we observed demonstrate that the
prenatal testes are more sensitive to long-term effects of radiation
exposure than adult testes are.
Although CP is a known teratogen and reproductive toxicant to
mammals after postnatal exposure, its prenatal effects on
spermatogenesis are relatively unknown. One study [29] indicated
that CP given to rats at day 12 of pregnancy affected the migration
of PGCs in the fetuses but did not follow the postnatal
development of the gonads. Our finding that a total dose of CP
of 15 mg/kg has long-term effects on spermatogenesis indicates
that male gonads at E10.5–E11.5 are much more sensitive to CP
than adult testes are [30]. Because spermatogenesis was sensitive to
radiation from E10.5 to birth, it is likely that spermatogenesis is
also sensitive to CP at these times. However, this remains to be
tested.
The sensitivity of oocyte and follicular numbers to CP treatment
was expected since the treatment that affected spermatogenesis
was given at E10.5-E11.5 when the PGCs were in undifferentiated
gonads. If depletion of PGCs was not compensated through extra
proliferation of oogonia, this must result in fewer oocytes in the
ovary. Studies investigating the exposure of female rat fetuses to
low doses of radiation [31] or busulfan [32] have shown that the
ovary is sensitive to these agents between E13.5 and 17.5. Hence,
it is likely that the ovary will be sensitive to CP throughout the
latter half of fetal development.
Because CP, like radiation, is a DNA-damaging agent, DNA
damage may be a common mechanism that leads to TGCT
formation and germ cell loss in embryonic gonads. The damage
produced by radiation and that caused by CP have some common
features. Radiation, either directly or through free radical/reactive
oxygen species, indirectly causes mainly single- and double-strand
breaks but also creates some base damage [33]. The CP
metabolite phosphoramide mustard forms adducts and interstrand
cross-links with DNA [34] and the metabolite acrolein produces
reactive oxygen species and DNA adducts [35]. The DNA damage
likely kills the PGCs leading to deficiencies in spermatogenesis and
ovarian reserves. In addition, in order to repair or bypass the DNA
damage, a DNA-damage-response pathway is activated and the
relationship of genes in this pathway to human testicular cancer
has been demonstrated in a genome-wide association study [36].
One possibility for the mechanism by which the DNA-damage
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response causes TGCT is that it interferes with the extensive
epigenetic changes occurring within the PGCs between E10.5 and
11.5 that are involved in the loss of pluripotency and commitment
to germ cell differentiation [14].
The role of genetic background in the induction of TGCT by
exogenous agents and its relation to spontaneous incidence was
assessed by comparing induction in 129 vs. L1 mice. Since tumors
were present in a high percentage of exposed testes and the
increased size indicated multiple tumor foci, it was necessary to
estimate the numbers of tumor foci per testis, taking into account
the Poisson distribution. The numbers of foci were much greater
in treated L1 mice (0.81 and 1.38, respectively, for CP and
radiation) than in 129 mice (0.19 and 0.16, respectively) (Table
S2). The data suggest that the increase in induced TGCTs by
DNA damaging agents is proportional to the spontaneous
incidence, and that the susceptibly to induction of TGCT in
humans would depend on the spontaneous incidence in different
ethnic backgrounds [37].
The mechanism by which radiation and CP cause spermato-
genic defects likely involves the killing of the PGCs or supporting
Sertoli cells. Whereas smaller testis could result from either fewer
Sertoli cells or spermatogonial stem cells to fill the niches, the
presence of atrophic tubules with morphologically normal Sertoli
cells (Fig. 1C & D) indicates that germ cells loss is the predominant
effect.
The reduction in ovarian follicle numbers we observed also
could have resulted from CP depleting the PGCs in undifferen-
tiated gonads. In addition, the higher ratio of developing follicles
to primordial follicles in CP-exposed mice compared to controls
demonstrates an increase in the rate of follicle recruitment, as has
been observed in rats in which exposure to busulfan in utero
depleted the primordial follicle pool [38]. This enhanced
activation of follicle recruitment may be a result of lower
concentrations of inhibitory factors produced from the lower
number of primordial follicles themselves [39] or from lower
amounts of anti-Mullerian hormone produced from reduced
numbers of developing preantral follicles [40]. The increased rate
of follicle recruitment would even further deplete the primordial
follicle pool as these mice aged; thus CP treatment in utero prior to
entry into meiosis may be a potential model for premature ageing
of the ovary.
The results of the present study have clinical importance, as
many pregnant women are diagnosed with breast cancer or other
life-threatening cancers requiring immediate treatment, which
usually includes DNA-damaging alkylating agents such as CP.
Within the last few years several groups have reported on more
than 400 children of women treated with chemotherapy during
the second and/or third trimesters [41–45]. The birth defect rate
and general health and growth in these children are not
significantly different from those of children whose mothers were
not treated with chemotherapy during these times. These children
included those of more than 100 women who received CP doses of
about 2,000 mg/m2, a part of FAC chemotherapy for breast or
gynecological cancer during pregnancy at The University of Texas
MD Anderson Cancer Center [15] (J.T. Litton, unpublished
communications). However, most of the children from the above
studies are currently prepubertal and still have not reached the age
at which the overt signs of possible adverse outcomes such as
testicular pathogenesis or ovarian insufficiency become apparent.
In humans the window of susceptibility of PGCs to tumorigenic
effects of DNA damaging agents is likely more prolonged than in
rodents. The reason being, in humans the transformation of
potentially pluripotent PGCs to committed germ cells, which starts
after the PGCs have arrived at the testes at 6 weeks of fetal
development, continues gradually throughout the rest of pregnan-
cy and even after birth [46]. Thus, although chemotherapy is
Table 3. Reproductive toxicity in male 129 and L1 mice exposed to cyclophosphamide (CP) or radiation in utero.
Mouse strain Treatment
No. analyzed testes
without TGCT
Weight of testis at
28 days (mg)
Testes with atrophic
tubules a
No. atrophic tubules
per cross section
129 b Control 159 5761 6 (4%) 1.760.2
129 b CP 87 4261 c 25 (32%) d 5.660.8 c
129 b Radiation 57 3861 c 18 (32%) d 4.860.8 c
L1 Control 72 6061 4 (6%) 1.560.5
L1 CP 13 4362 c 5 (38%) d 2.460.5
L1 Radiation e 13 3761 c 2 (15%) 3.560.5
aValues given as absolute number and percentage of testes analyzed
bData from 129S5 and 129S1/SvImJ mice were pooled.
cSignificantly different between treated and control mice (P,0.05; t-test).
dSignificantly different between treated and control mice (P,0.05; Fisher’s exact test).
eData from previous study [5] was included for comparison.
doi:10.1371/journal.pone.0093311.t003
Table 4. Reduction of testis weights and sperm counts in 8-week-old 129S1/SvImJ mice exposed to cyclophosphamide (CP) in
utero.
Treatment Testis weight (mg) Sperm head count/testis Sperm count/cauda epididymis
Control (n = 5) 9762 29 (62)6 106 10.2 (60.8)6 106
CP (n = 4) 7561 a 18 (62)6 106 a 7.1 (60.5)6 106 a
aSignificantly different between treated and control mice (P,0.01; t-test).
doi:10.1371/journal.pone.0093311.t004
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given during the second and third trimesters, the germ cells are still
susceptible to the toxic and tumorigenic effects of chemotherapy.
It is important to consider how to extrapolate the possible
detrimental effects of CP found in the present study to human. If
human males exposed to CP in utero have a 6-fold increase in
testicular cancer incidence, as was observed in the mice in the
present study, the cumulative incidence of testicular cancer in men
up to age 44 years would be increased from about 3 per 1000 to
about 18 per 1000 males [47]. To detect such an effect, a large
study is required with long-term follow up, as most of the testicular
cancers occur after puberty. However, because the cumulative CP
dose to pregnant women (2,000 mg/m2) [15] is 40 times that given
to mice in the present study (50 mg/m2), the testicular cancer
incidence could be higher and thus more readily detectable. In any
case, the effects of CP on reproductive function may be more
widespread and easier to detect in limited populations.
Because the effects, if any, of in utero exposure in humans remain
uncertain, physicians should use noninvasive markers of possible
negative outcomes. Spermatogenic potential in the prepubertal
males could be assessed by measurements of testicular size.
Normal pubertal development of males is expected because the
absence of germ cells does not interfere with puberty, and in
postpubertal males, follicle stimulating hormone and inhibin B
levels, and sperm counts could be measured. In prepubertal girls
anti-Mullerian hormone levels [22] should be measured to assess
the ovarian reserve and data should be obtained on puberty,
menarche, the regularity of subsequent menses, and subsequent
fertility to evaluate the overall reproductive potential. The present
study’s results underscore the urgency of testing these reproductive
parameters in boys and girls so that patients who will likely be
given CP can be properly counseled about the potential risks of the
drug to their unborn children, and appropriate measures taken to
reduce any consequences.
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